Dupilumab for Atopic Dermatitis

Dupilumab (brand name Dupixent) is shaping up to be a game-changer in the treatment of atopic dermatitis, often referred to informally as “eczema”. Dupixent addresses an underlying immune dysregulation that contributes to the development of atopic dermatitis. It blocks IL-4 and IL-13, two important cytokines in the TH2 pathway. In a clinical trial, after 12… Read More